Montreux Equity Partners, based in Menlo Park, CA, is a life sciences focused venture capital firm that invests in pharmaceutical and medical device companies. Montreux’s goal is to generate significant capital gains for both our investors and the entrepreneurs that we support. Montreux is currently investing out of our fourth fund, MEP IV, a $250 M fund.

The firm’s investment team brings more than 70 years of operating and investing experience as entrepreneurs, managers and investors of life sciences focused companies. Montreux investment professionals have been involved as founders, investors and board members in more than 45 life science companies over the past 20 years including Oclassen Pharmaceuticals (sold to Watson Pharmaceuticals in 1997), Target Therapeutics (sold to Boston Scientific in 1997), Prograft Medical (sold to W.L. Gore in 1997), Innovasive Devices (sold to Johnson & Johnson in 1998), Collagen (sold to Inamed in 1999), ProDuct Health (sold to Cytyc in 2001), Interventional Technologies (sold to Boston Scientific in 2001), Enteric Medical (sold to Boston Scientific in 2002), Conceptus (NASDAQ: CPTS), Integrated Biosystems (sold to STEDIM in 2004), Coalescent Surgical (sold to Medtronic in 2004), Peninsula Pharmaceuticals (sold to Johnson & Johnson in 2005), Somaxon Pharmaceuticals (NASDAQ: SOMX), Cerexa (sold to Forest Laboratories, 2007), Neurogesx (NASDAQ: NGSX), Orexigen Therapeutics (NASDAQ: OREX), NovaCardia (sold to Merck, 2007) and Aryx Therapeutics (NASDAQ: ARYX).